Rituximab as a treatment option for refractory endogenous anterior uveitis.

Abstract

BACKGROUND:

To report on anti-CD20 antibody therapy in a patient with uveitis refractive to immunosuppression therapy.

METHODS:

Case report with ophthalmoscopic, optical coherence tomography and fluorescein-angiographic findings.

RESULTS:

A 49-year-old woman was suffering from bilateral, noninfectious chronic anterior uveitis refractive to corticosteroids and immunosuppressive drugs. Bilateral visual acuity was 20/100 due to cataract and cystoid macular edema (CME). After treatment with rituximab, vision and CME improved, and uveitis was stable until the final visit (follow-up at 12 months).

CONCLUSION:

The case report suggests that rituximab may be helpful for selected patients with chronic anterior uveitis refractive to corticosteroids and immunosuppressive medication.

• Authors: C Tappeiner, C Heinz, C Specker, A Heiligenhaus
• Journal: Ophthalmic research (Ophthalmic Res) Vol. 39 Issue 3 Pg. 184-6 ( 2007) ISSN: 0030-3747 [Print] Switzerland
• PMID: 17534119 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antigens, CD20
• Immunologic Factors
• Rituximab

Topics

• Antibodies, Monoclonal (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Antigens, CD20
• Chronic Disease
• Female
• Fluorescein Angiography
• Follow-Up Studies
• Fundus Oculi
• Humans
• Immunologic Factors (administration & dosage, therapeutic use)
• Infusions, Intravenous
• Middle Aged
• Ophthalmoscopy
• Rituximab
• Tomography, Optical Coherence
• Uveitis, Anterior (drug therapy, pathology)